Equifax Collateral Value Connector(TM) Leverages Southwest

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Equifax Collateral Value Connector(TM) Leverages Southwest Financial Services to Optimize Valuation Accuracy, Reduce Collateral Valuation & Compliance Risk for Lenders

ATLANTA, July 29, 2013 (GLOBE NEWSWIRE) -- Equifax (NYSE: EFX ) announced the availability of its Collateral Value Connector ™, an AVM cascade that rank orders the industry's leading automated valuation models (AVMs) by accuracy to provide lenders a precise collateral valuation that can be depended on. In an effort to provide the lending community with a truly transparent and documented approach to AVM testing and facilitate compliance with federal regulatory guidelines, Equifax has partnered with Southwest Financial Services, Ltd. to independently test and validate the AVMs that are available via the Collateral Value Connector.

As a national provider of appraisal management, title, flood zone determination and valuation services, Southwest Financial Services is uniquely qualified to independently test and make sound recommendations as it relates to which AVM(s) a lender should consider using given the geographic location of an asset. Through exhaustive testing that takes place on a weekly basis, Southwest Financial Services is able to measure the performance of the models that are available via the Collateral Value Connector and rank them at the county-level according to their respective accuracy rates to ensure delivery of the most accurate collateral valuation possible. In previous years, loose AVM testing standards led to the use of inaccurate and unsupported collateral valuations, which in turn increased fraud, repurchase, and reputational risk for lenders. However, today's strict Interagency Appraisal and Evaluation Guidelines mandate comprehensive testing policies for lenders to justify the use of an AVM according to how it has performed in a given subject property's geographic area.  

For first mortgage underwriting, an AVM's accuracy plays a significant role in the appraisal review process, but for home equity lending, its role is more critical. In some cases, federal and state regulators permit the use of AVMs in lieu of appraisals for home equity lending due to the difference in risk exposure and cost of the appraisal process relative to the total loan amount. For lenders, Collateral Value Connector comes at a time when home equity volumes are increasing, there is significant competition to offer consumers home equity products at a competitive rate, and regulatory scrutiny over the collateral valuation process is at an all-time high. According to the Equifax July National Consumer Credit Trends Report , new home equity loan volumes year-to-date in April 2013 increased more than 17% year over year, from $24.1 billion to $28.4 billion. 

"With today's low rates and increasing home values in the vast majority of areas in the US, homeowners are returning to leverage the equity in their home as a flexible source of credit," said Craig Crabtree, Senior Vice President Equifax Mortgage Services . "For lenders, the need for valuation accuracy and transparency is more important than ever. Through Southwest Financial Services' independent and comprehensive testing criteria, the Equifax Collateral Value Connector exceeds the standard automated valuation model to deliver an unparalleled level of accuracy, coverage and documentation that lenders can rely on to effectively manage their collateral risk and meet regulatory compliance demands."

About Equifax, Inc.

Equifax is a global leader in consumer and commercial information solutions, providing businesses of all sizes and consumers with information they can trust. We organize and assimilate data on more than 500 million consumers and 81 million businesses worldwide, and use advanced analytics and proprietary technology to create and deliver customized insights that enrich both the performance of businesses and the lives of consumers.

Headquartered in Atlanta, Equifax operates or has investments in 18 countries and is a member of Standard & Poor's (S&P) 500® Index. Its common stock is traded on the New York Stock Exchange (NYSE) under the symbol EFX . For more information, please visit www.equifax.com/property .

Demitra Wilson (404) 885-8907

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

PotlatchDeltic Reveals Tax Implications for 2024 Shareholder Dividends

Updated Category News Views 247

PotlatchDeltic Reveals Dividend Tax Treatment for 2024 PotlatchDeltic Corporation (Nasdaq: PCH) is stepping into the spotlight by announcing the tax treatment for its anticipated dividend distributions throughout the year. As a prominent player in the real estate investment sector, this announcement brings clarity to investors regarding how dividends will be categorized...

Continue Reading
Beyond Air Secures $3.25 Million from Warrant Exercises

Updated Category News Views 158

Beyond Air's Strategic Moves to Boost Capital Beyond Air, Inc. (NASDAQ: XAIR), a leading medical device and biopharmaceutical company, is making waves in the financial realm. Focused on the innovative use of nitric oxide (NO) to enhance patient care, Beyond Air has announced the immediate exercise of certain outstanding warrants, aiming to generate approximately $3.25...

Continue Reading
Dr. Sven Kili Joins Saisei Ventures as New Partner

Updated Category News Views 194

Saisei Ventures Welcomes Dr. Sven Kili as Partner Saisei Ventures, a prominent investment firm focused on the advancement of biotechnology and therapeutic innovations, has announced an exciting new chapter in its journey. Dr. Sven Kili, MD, has been appointed as a partner, marking a significant addition to the team's leadership. Dr. Kili, who played an advisory role since...

Continue Reading
MangoRx Unveils Innovative Tirzepatide Tablet for Weight Loss

Updated Category News Views 192

Mangoceuticals, Inc. (NASDAQ: MGRX) launched its new oral Tirzepatide tablet, TRIM, back in 2024 at a steep price of $399 per month. Traders noticed this shift towards a convenient alternative to traditional injectables and were already debating the long-term implications on sales and market share. TRIM's Role: A Game Changer for Weight Management? Tirzepatide has made...

Continue Reading
Mama’s Creations Q2 FY2025 Earnings Call Announcement

Updated Category News Views 77

Mama’s Creations to Host Earnings Call for Second Quarter FY2025 Mama’s Creations, Inc. (NASDAQ: MAMA), a leading national marketer and manufacturer of fresh deli prepared foods, is preparing to announce its financial results for the fiscal second quarter, which ended on July 31. The earnings call is scheduled to take place after the market closes on September 10....

Continue Reading